Siga Technologies INC 10-Q quarterly reports

SIGA Technologies reports a substantial year-over-year decline in revenue and net income for the second quarter of 2026, primarily driven by lower product sales compared to the prior year's strong performance.

SIGA Technologies reports a net loss of $3.45 million for Q1 2026, with revenues declining to $6.24 million, impacted by shifts in product sales and increased R&D expenses.

SIGA Technologies reported a net loss in Q3 2025, driven by decreased product sales and increased R&D expenses, while year-to-date performance remained strong despite negative mpox clinical trial results.

SIGA Technologies announced a substantial increase in Q2 2025 revenues and net income, primarily driven by robust TPOXX sales to the U.S. Government, despite ongoing regulatory scrutiny regarding its mpox efficacy.

SIGA Technologies' Q1 2025 revenue decreased compared to Q1 2024, primarily due to lower product sales, while the company continues to advance its government contracts and pursue label expansion for TPOXX.

SIGA Technologies saw a significant increase in revenue for the nine months ended September 30, 2024, primarily driven by product sales to the U.S. government and international markets.

SIGA Technologies reports a significant increase in revenue for the second quarter of 2024, primarily driven by sales of IV TPOXX to the U.S. government.

SIGA Technologies saw a significant increase in revenue and a return to profitability in the first quarter of 2024, driven by higher product sales.